Veru enters clinical supply deal with Novo Nordisk for enobosarm-Wegovy obesity trial
PUBT · 8h ago
Share
Listen to the news
- Veru entered a clinical supply agreement with Novo Nordisk on June 2, 2026 to support its Phase 2b PLATEAU obesity study.
- Novo Nordisk will provide Wegovy at no charge for use in the trial combining Wegovy with enobosarm in older adults.
- Veru will sponsor and run the study, providing Novo Nordisk trial-design and clinical-conduct insights, including protocol and safety updates.
- The deal grants Novo Nordisk a right of first negotiation on any future enobosarm combination with its GLP-1 products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-019478), on June 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved